Contemporary Algorithms for the Diagnosis and Treatment of Multiple Sclerosis Based on Individual Assessment of Patients’ Status

Бойко, А. Н.; Гусев, Е. И.

doi:10.1007/s11055-018-0642-0

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Российская клиническая практика также опирается на критерии неэффективности терапии ПИТРС, опубликованные в 2014 и 2018 гг., в которых учтены категории как субоптимального ответа, так и отсутствия ответа на проводимую терапию (табл. 2) [6,7] ство селективной терапии иммунореконституции, зарегистрированный на территории Российской Федерации в марте 2020 г. для лечения пациентов с ВАРС.…”

Section: Recommendations For Switching Patients With Highly Active Muunclassified

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Totolyan

Алифирова

Bakhtiyarova

et al. 2020

RJTAO

View full text Add to dashboard Cite

The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS.

show abstract

Section: Recommendations For Switching Patients With Highly Active Muunclassified

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Totolyan

Алифирова

Bakhtiyarova

et al. 2020

RJTAO

View full text Add to dashboard Cite

show abstract

Contemporary Algorithms for the Diagnosis and Treatment of Multiple Sclerosis Based on Individual Assessment of Patients’ Status

Cited by 1 publication

References 61 publications

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

Contact Info

Product

Resources

About